Table 2.
Factors associated with adherence to recommended surveillance (i.e., completion of an echocardiogram over the last 5 years) among survivors at high risk for cardiomyopathy (n = 930).
| Total number | Adherence, n (%) | Crude RR (95% CI) | Adjusted RRa (95% CI) | |
|---|---|---|---|---|
| Sex | ||||
| Females (ref) | 406 | 161 (39.7) | 1 | 1 |
| Males | 524 | 133 (25.4) | 0.64 (0.53–0.77)*** | 0.71 (0.58–0.86)*** |
| Age (years) | ||||
| <36 | 275 | 98 (35.6) | 1 | 1 |
| 36–49 | 555 | 153 (27.6) | 0.77 (0.63–0.95)* | 0.79 (0.64–0.98)* |
| ≥50 | 100 | 43 (43.0) | 1.21 (0.92–1.59) | 1.09 (0.82–1.46) |
| Deprivation score | ||||
| Quintiles 1 and 2 (ref) | 364 | 131 (36.0) | 1 | 1 |
| Quintiles 3 | 216 | 70 (32.4) | 0.90 (0.71–1.14) | 0.96 (0.76 –1.21) |
| Quintile 4 | 187 | 51 (27.3) | 0.76 (0.58–0.99)* | 0.84 (0.64–1.10) |
| Quintile 5 (most deprived) | 163 | 42 (25.8) | 0.72 (0.53–0.96)* | 0.79 (0.59–1.05) |
| Childhood cancer | ||||
| Wilms tumour (ref) | 133 | 51 (38.4) | 1 | 1 |
| Neuroblastoma | 66 | 12 (18.2) | 0.47 (0.27–0.83)** | 0.53 (0.30–0.91)* |
| Hodgkin’s lymphoma | 64 | 20 (31.3) | 0.82 (0.53–1.24) | 0.72 (0.47–1.11) |
| Non-Hodgkin’s lymphoma | 212 | 56 (22.8) | 0.69 (0.50–0.94)* | 0.72 (0.52–1.00) |
| Soft tissue sarcoma | 139 | 40 (28.8) | 0.75 (0.53–1.05) | 0.75 (0.53–1.05) |
| Bone sarcoma | 204 | 82 (40.2) | 1.05 (0.80–1.38) | 1.01 (0.75–1.35) |
| CNS tumour | 45 | 7 (15.6) | 0.41 (0.20–0.83)* | 0.43 (0.21–0.89)** |
| Other solid cancersb | 67 | 26 (38.8) | 1.00 (0.70–1.47) | 0.99 (0.69–1.44) |
| Age at diagnosis | ||||
| <5 years (ref) | 298 | 80 (26.9) | 1 | 1 |
| ≥5 years | 632 | 214 (33.9) | 1.26 (1.02–1.57)* | 1.27 (1.01–1.62)* |
| Anthracycline dose >250 mg/m2 | ||||
| No (ref) | 144 | 41 (28.5) | 1 | – |
| Yes | 786 | 253 (32.2) | 1.13 (0.86–1.49) | – |
| Cardiac radiation ≥30 Gy to ≥10% of the LV volume | ||||
| No (ref) | 778 | 246 (31.6) | 1 | – |
| Yes | 152 | 48 (31.6) | 1.00 (0.79–1.29) | – |
| Second cancer | ||||
| No (ref) | 844 | 252 (29.9) | 1 | 1 |
| Yes | 86 | 42 (48.8) | 1.65 (1.29–2.09)*** | 1.43 (1.13–1.82)** |
CI confidence interval, CNS central nervous system, FDep French deprivation index, NA non-available, RR relative risk, SD standard deviation.
aAdjusted for all other variables in the multivariable modified Poisson regression model.
bGonadal tumour, thyroid tumour, retinoblastoma and other types of carcinoma.
*P value < 0.05; **P value < 0.01; ***P value < 0.001.